With deCODE genetics, Inc. Deal, Amgen Aims to Discover Drugs Like We Meant to in 1999

It certainly wasn’t the deal Amgen investors were expecting from their new executive team: This morning, the Thousand Oaks, Calif., biotechnology giant dropped $415 million on DeCode Genetics, a genomics firm that Wall Streeters associate with the hype-filled days of the 2000s genomics boom and a company they probably hadn’t thought about since it went bankrupt in 2010.

Back to news